文献速递中医内科中药与中成药合理使用

冠心宁片联合阿司匹林减少PCI后心血管事件的整群随机试验

Guanxinning tablets plus aspirin versus aspirin monotherapy to reduce cardiovascular events after percutaneous coronary intervention: A cluster-randomized controlled trial (GAP trial).
PubMed 文献 · Phytomedicine · 2025-10-30

GAP试验在中国63家三级医院纳入3586例PCI后已完成至少12个月DAPT的冠心病患者,按2:1整群随机接受冠心宁片联合阿司匹林或单用阿司匹林治疗12个月并随访12个月。中位随访23个月,联合组主要复合终点发生率显著低于单药组(11.0% vs 13.2%,校正HR 0.79,95%CI 0.63-0.98),大出血事件罕见且两组相似。

要点

  • PCI后DAPT满12个月的冠心病患者,冠心宁片联合阿司匹林可降低主要心血管复合终点。
  • 联合组血运重建和因不稳定心绞痛再住院率均低于单用阿司匹林组。
  • 联合治疗未增加大出血事件,支持其作为延长DAPT的潜在替代策略。

核心结论

  • 冠心宁片联合阿司匹林可减少PCI后心血管不良事件,且不增加出血,支持其作为延长DAPT的潜在替代策略。

研究设计与样本

  • 开放标签整群随机对照试验,2017年3月至2018年12月在中国63家三级医院开展。
  • 共纳入3586例PCI后已完成至少12个月DAPT的冠心病患者,医院和参与者按2:1随机分配。
  • 联合组2389例接受冠心宁片加阿司匹林,单药组1197例单用阿司匹林,治疗12个月后再随访12个月。
  • 主要终点为心血管死亡、非致死性心肌梗死、支架血栓、血运重建、缺血性卒中及不稳定心绞痛再住院的复合终点。
  • 结局评估者和数据分析者设盲,采用意向性治疗分析并考虑ICC。

主要发现

  • 中位随访23个月,联合组主要复合终点发生率为11.0%,单药组为13.2%,校正HR 0.79(95%CI 0.63-0.98)。
  • 联合组血运重建率为3.8%,单药组为4.7%。
  • 联合组因不稳定心绞痛再住院率为7.0%,单药组为9.7%。
  • 大出血事件罕见且两组发生率相似。

临床怎么用

  • 对PCI后已完成至少12个月DAPT、需降阶为阿司匹林单药的冠心病患者,可考虑联合冠心宁片以进一步降低缺血事件风险。
  • 联合用药期间仍应关注出血风险,尽管本试验中大出血事件罕见且与单药组相似。

局限性

  • 研究为开放标签设计,虽结局评估者和数据分析者设盲,但非双盲可能引入偏倚。
  • 研究仅在中国三级医院开展,结果外推至其他人群或医疗环境需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prolonged dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) lowers thrombotic risk but increases bleeding, creating a therapeutic dilemma. Guanxinning tablets (GXNT), a traditional Chinese medicine with antithrombotic and cardioprotective effects, may offer an alternative strategy. PURPOSE: To evaluate whether GXNT combined with aspirin reduces cardiovascular events without increasing bleeding in patients transitioning from DAPT to aspirin monotherapy after PCI. STUDY DESIGN: An open-label, cluster-randomized controlled trial conducted in 63 tertiary hospitals in China between March 2017 and December 2018. METHODS: A total of 3586 patients with coronary heart disease (CHD) who had completed at least 12 months of DAPT following PCI were enrolled. Hospitals and participants were randomized in a 2:1 ratio to receive GXNT plus aspirin or aspirin alone for 12 months, followed by 12 months of additional follow-up. The primary endpoint was a composite of cardiovascular death, non-fatal myocardial infarction, stent thrombosis, revascularization, ischemic stroke, and rehospitalization for unstable angina. Outcome assessors and data analysts were blinded to treatment allocation. The intention-to-treat analysis principle was adopted, and ICC were accounted for in the statistical analysis. RESULTS: Of the participants, 2389 received GXNT plus aspirin and 1197 received aspirin alone. After a median follow-up of 23 months, GXNT significantly reduced the primary outcome (11.0 % vs. 13.2 %; adjusted hazard ratio [HR] 0.79, 95 % confidence interval [CI] 0.63-0.98). Rates of revascularization (3.8 % vs 4.7 %) and rehospitalization for unstable angina (7.0 % vs 9.7 %) were also lower in the GXNT group. Major bleeding events were rare and similar across groups. CONCLUSION: GXNT combined with aspirin reduced adverse cardiovascular events after PCI without increasing bleeding, supporting its potential as an alternative to prolonged DAPT.

来源:Phytomedicine,查看原文。版权归原作者所有。

引用

  1. Xu H, Li J, Zhao Y, et al. Guanxinning tablets plus aspirin versus aspirin monotherapy to reduce cardiovascular events after percutaneous coronary intervention: A cluster-randomized controlled trial (GAP trial). Phytomedicine. 2025. PMID: 41240536. doi:10.1016/j.phymed.2025.157500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。